On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Can-Fite BioPharma Ltd. (NYSEMKT:CANF), Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), BioDelivery Sciences International, Inc. (NASDAQ:BDSI), Gevo, Inc. (NASDAQ:GEVO)
Can-Fite BioPharma Ltd. (NYSEMKT:CANF), with shares declined - -60.29%, closed at $2.20.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), with shares dropped -28.94%, settled at $3.83.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), with shares dipped -24.33%, and closed at $10.51.
Gevo, Inc. (NASDAQ:GEVO), plummeted -15.04%, and closed at $0.212.
Latest NEWS regarding these Stocks are depicted underneath:
Can-Fite BioPharma Ltd. (NYSEMKT:CANF)
Can-Fite BioPharma Ltd. (CANF), declared that its Phase II/III psoriasis trial for the Corporation’s drug candidate CF101 did not achieve its primary endpoint.
“We are disappointed that our trial did not meet its primary endpoint. Regretfully, in the PASI 75 and PGA we did not see any real effect in patients over placebo. We have not yet accomplished our analysis of secondary endpoint and sub-group analysis and intend to complete it in the near future. Can-Fite is ongoing its research and development efforts in relation to its drugs and indications in the pipeline.” stated Can-Fite CEO Dr. Pnina Fishman.
Can-Fite BioPharma, Ltd., a clinical-stage biotechnology corporation, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
On Friday, Adamis Pharmaceuticals Corporation (ADMP), declared that recently it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product, for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction. On May 28, 2014, Adamis presented an NDA to the FDA following Section 505(b)(2) of the Food, Drug & Cosmetic Act, as amended, for approval of the Epinephrine PFS product.
Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We are reviewing the CRL and plan to request a meeting with the FDA to talk about the letter, counting clarifying the product delivery volume specifications. Although we expect to have more clarity with respect to timing, we believe we can satisfy all of the requests in the CRL and will work closely with the FDA to address the items raised in the CRL and finalize its review of our NDA. Adamis remains committed to bringing the epinephrine PFS to market.”
Adamis Pharmaceuticals Corporation, a biopharmaceutical corporation, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences International, Inc. (BDSI), declared that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel contrast to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically noteworthy improvement over placebo. In addition, a strong safety profile for the product was observed. The results of this trial provide data that will allow the corporation to better refine the protocol criteria to capture a more “enriched” patient population and target site selection.
“Based on the results of our formerly declared positive interim analysis, this outcome was unpredictable,” said Dr. Andrew Finn, Executive Vice President of Product Development. “The interim analysis data showed a difference contrast to placebo of -0.94 with a standard deviation of 2.2 which was close to our study assumption of -1.0 and 1.8, respectively, and very similar to the preceding Phase 2 study conducted by our licensor Arcion.”
BioDelivery Sciences International, Inc., a specialty pharmaceutical corporation, engages in the development and commercialization of pharmaceutical products principally in the areas of pain administration and addiction. The corporation provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which comprises of a small, bi-layered erodible polymer film for application to the buccal mucosa.
Gevo, Inc. (NASDAQ:GEVO)
On Thursday, Gevo, Inc. (GEVO), declared its financial results for the three months ended December 31, 2014 and offered an update on recent corporate highlights.
Proceeds for the fourth quarter of 2014 were $9.5 million contrast to $1.7 million in the same period in 2013. The raise in proceed during 2014 is primarily a result of the production and sale of about $8.8 million of ethanol and distiller’s grains following the transition of the Luverne plant to the SBS configuration.
Cost of goods sold raised by $5.8 million during the three months ended December 31, 2014, as contrast to the same quarter in 2013, due primarily to the raised production activity at the Luverne plant under the SBS configuration. Gross loss was $1.4 million for the three months ended December 31, 2014. After adding back $1.4 million of depreciation expense, the cash gross margin was a positive $0.1 million for the fourth quarter of 2014.
Gevo, Inc., a renewable chemicals and biofuels corporation, focuses primarily on the production and sale of isobutanol and related products from renewable feedstocks. Isobutanol is a four-carbon alcohol, which is used as a specialty chemical in the production of solvents, paints, and coatings or as a value-added gasoline blendstock.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
